Jeff Gross

Dr. Jeff Gross is responsible for leading all aspects of product development in concert with consultants in the areas of R&D, QA, manufacturing, RA and reimbursement for the first product indication, TKA, developing a robust pipeline of line extensions and new products, continual development of the company’s IP portfolio, and working with the CEO on fund raising and corporate partnership activities.

Jeff brings over 30 years of experience in medical device R&D, M&A and commercialization experience launching cardiovascular, vascular, interventional, spinal, infection protection, and wound healing products. He most recently was a Senior Vice President, R&D, Product Engineering and Chief Technology Officer at Procedural Solution, where he led a multidisciplinary R&D organization of engineers, biologists, chemists, clinical specialists and technicians located in three countries at seven sites conducting medical device, drug, and combination drug/device R&D and product engineering and launched several products that generated about $45 million per year in new product revenue year during this time period with substantive further growth possible. Prior to that, he worked as Senior Vice President, Research and Development, Corporate Officer at Angiotech Pharmaceuticals.

He is a seasoned senior executive within Class II and III medical devices, drugs and device/drug combination products who has direct knowledge in the research, product development, pre-clinical testing, clinical trials, and intellectual property management of new products. Jeff also has over 50 patents & patents pending.

Jeff holds a Doctorate of Biomedical Engineering from The University of Memphis, a Master of Science from University of Houston, and a Bachelor of Science from Georgia Institute of Technology.